Analysts Set TriSalus Life Sciences, Inc. (NASDAQ:TLSI) PT at $10.93

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) have earned an average recommendation of “Buy” from the nine research firms that are presently covering the firm, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $10.93.

TLSI has been the topic of a number of recent research reports. Lake Street Capital initiated coverage on shares of TriSalus Life Sciences in a report on Thursday, February 13th. They issued a “buy” rating and a $10.00 price objective on the stock. Canaccord Genuity Group restated a “buy” rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a report on Friday, March 28th. Finally, Roth Mkm restated a “buy” rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a report on Friday, January 24th.

Hedge Funds Weigh In On TriSalus Life Sciences

A number of hedge funds have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. bought a new position in shares of TriSalus Life Sciences during the first quarter valued at approximately $55,000. Renaissance Technologies LLC bought a new position in shares of TriSalus Life Sciences during the fourth quarter valued at approximately $67,000. Connective Capital Management LLC bought a new position in shares of TriSalus Life Sciences during the fourth quarter valued at approximately $140,000. Northern Trust Corp boosted its stake in shares of TriSalus Life Sciences by 22.7% during the fourth quarter. Northern Trust Corp now owns 32,112 shares of the company’s stock valued at $161,000 after purchasing an additional 5,936 shares in the last quarter. Finally, Goldman Sachs Group Inc. bought a new position in shares of TriSalus Life Sciences during the first quarter valued at approximately $187,000. 2.58% of the stock is currently owned by institutional investors.

TriSalus Life Sciences Stock Performance

Shares of NASDAQ:TLSI opened at $5.14 on Wednesday. The firm has a market capitalization of $165.88 million, a PE ratio of -2.06 and a beta of 0.50. The firm has a fifty day moving average of $5.40 and a 200 day moving average of $4.99. TriSalus Life Sciences has a 52-week low of $3.50 and a 52-week high of $10.17.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.13). The firm had revenue of $9.17 million for the quarter, compared to analysts’ expectations of $9.04 million. During the same period last year, the business posted ($0.60) earnings per share. On average, sell-side analysts forecast that TriSalus Life Sciences will post -1.55 EPS for the current fiscal year.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.